Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 161

Another blood cell tumor treated by stem cells is lymphomas, including Hodgkin’s lymphoma, multiple myeloma, and non-Hodgkin’s lymphoma.

Hodgkin’s lymphoma is a tumor of the lymphocytes characterized by Reed-Sternberg cells and is classified as two types: classical (nodular sclerosing, mixed cellularity, lymphocyte predominant, and lymphocyte depleted types) and the rare nodular lymphocyte-predominant disease. Advanced or relapsing Hodgkin’s lymphoma is treated by aggressive chemotherapy followed by stem cell replacement; it is usually preferred to utilize the patient’s own cells as compared to finding a donor.

Non-Hodgkin’s lymphomas usually are tumors of the B cells, rarely of T cells. Common B-cell tumors are diffuse large B cell lymphoma and follicular lymphoma. As with Hodgkin’s lymphomas, refractory or relapsed tumors are usually treated with autologous transplantation, however the adverse effects still run high with this treatment.

Multiple myeloma, a cancer of the antibody-producing plasma cells, leads to bone pain and fractures, anemia, infections, neurological impairment, and renal failure. Compared to the traditional treatment of chemotherapy being adopted over the years, new trials have shown the promise of autologous stem cell transplants following aggressive chemotherapy, the stem cell rescue treatment modality.